MK-677 CAPSULES 12.5MG - 60CT
MK-677 (Ibutamoren) is an orally active, non-peptide growth hormone secretagogue that functions as a ghrelin receptor agonist. Preclinical studies in cell cultures and animal models indicate that MK-677 stimulates pulsatile growth hormone (GH) release from the pituitary, leading to sustained elevation of circulating GH and IGF-1 levels, without significant impact on cortisol or prolactin.[1][2]
Key Research Areas
- Growth Hormone & IGF-1 Axis Activation – In rodent and canine models, MK-677 administration has been shown to induce dose-dependent increases in GH pulses and prolonged elevation of IGF-1 concentrations, supporting research into sustained GH signaling mechanisms.[3][4]
- Metabolic & Body Composition Effects – Preclinical investigations demonstrate enhanced nitrogen retention, increased lean mass, and improved fat utilization in animal models of growth hormone modulation.[5][6]
- Bone & Tissue Maintenance Pathways – Animal studies suggest MK-677 may promote bone density and turnover markers, as well as support muscle protein synthesis and recovery processes through elevated GH/IGF-1 pathways.[7][8]
Product Specifications
| Form |
Capsules (research use only) |
| CAS Number |
159752-10-0 |
| Molecular Formula |
C27H36N4O5S |
| Molar Mass |
528.66 g/mol |
| Synonyms |
Ibutamoren, MK-0677, Nutrobal |
| Purity |
≥99% (HPLC) |
| Storage |
Room temp, protect from light and moisture |
| Other Details |
Excipients: Research-grade fillers/capsule material |
References
- 1. Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996. PubMed
- 2. Murphy MG, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover and bone mineral density in obese and elderly adults. J Clin Endocrinol Metab. 1998. PubMed
- 3. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998. PubMed
- 4. Copinschi G, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. 1996. PubMed
- 5. Sigalos JT, et al. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed
- 6. Veldhuis JD, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. Growth Horm IGF Res. 2010. PubMed
- 7. Svensson J, et al. Oral administration of growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure in healthy elderly subjects. J Clin Endocrinol Metab. 1998. (Related metabolic data)
- 8. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Ann Intern Med. 2008. (Contextual GHS study)
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
